{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:23Z","timestamp":1791924203504,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","award":["IRB24-0901"],"award-info":[{"award-number":["IRB24-0901"]}],"id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xkme.2025.101141","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:21:20Z","timestamp":1760145680000},"page":"101141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chimeric Antigen Receptor T-Cell Therapy in Dialysis-Dependent Patients With Multiple Myeloma: Insights From a 5-Case Series"],"prefix":"10.1016","volume":"7","author":[{"given":"Varsha","family":"Swamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay L.","family":"Koyner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Derman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9087-9730","authenticated-orcid":false,"given":"Marco","family":"Bonilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.xkme.2025.101141_bib1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-022-00266-1","article-title":"Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis","volume":"11","author":"Hunter","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"10.1016\/j.xkme.2025.101141_bib2","doi-asserted-by":"crossref","first-page":"829.e1","DOI":"10.1016\/j.jtct.2022.09.009","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.xkme.2025.101141_bib3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.xkme.2025.101141_bib4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2024","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.xkme.2025.101141_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100856","article-title":"Chimeric antigen receptor (CAR) T-cell therapy use in patients with multiple myeloma and kidney failure on maintenance hemodialysis: a report of 2 cases","volume":"6","author":"Pak","year":"2024","journal-title":"Kidney Med"},{"issue":"5","key":"10.1016\/j.xkme.2025.101141_bib6","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00277-023-05163-z","article-title":"Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis","volume":"102","author":"W\u00e4sch","year":"2023","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.xkme.2025.101141_bib7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.xkme.2025.101141_bib8","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41434-018-0019-6","article-title":"Fludarabine and neurotoxicity in engineered T-cell therapy","volume":"25","author":"Lowe","year":"2018","journal-title":"Gene Ther"},{"issue":"5","key":"10.1016\/j.xkme.2025.101141_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2165\/00003495-199345050-00009","article-title":"Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy","volume":"45","author":"Ross","year":"1993","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.xkme.2025.101141_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/23993693231181728","article-title":"Chimeric antigen receptor T-cell therapy in a dialysis patient with lymphoma","volume":"7","author":"Mire","year":"2023","journal-title":"J Onco-Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2025.101141_bib11","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41409-018-0260-z","article-title":"Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients","volume":"54","author":"Chung","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2025.101141_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1600-0609.2005.00439.x","article-title":"Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure","volume":"74","author":"Kielstein","year":"2005","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.xkme.2025.101141_bib13","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbmt.2007.08.050","article-title":"Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics","volume":"13","author":"Horwitz","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.xkme.2025.101141_bib14","first-page":"226","article-title":"Clinical pharmacology of cyclophosphamide","volume":"33","author":"Bagley","year":"1973","journal-title":"Cancer Res"},{"key":"10.1016\/j.xkme.2025.101141_bib15","article-title":"Cyclophosphamide pharmacogenomic variation in cancer treatment and its effect on bioactivation and pharmacokinetics","volume":"2024","author":"El-Serafi","year":"2024","journal-title":"Adv Pharmacol Pharm Sci"},{"issue":"4","key":"10.1016\/j.xkme.2025.101141_bib16","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.xkme.2025.101141_bib17","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/cas.14933","article-title":"Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: a comprehensive review","volume":"112","author":"Yasuda","year":"2021","journal-title":"Cancer Sci"},{"issue":"6","key":"10.1016\/j.xkme.2025.101141_bib18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00280-015-2727-6","article-title":"Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites","volume":"75","author":"Darwish","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4 suppl 13","key":"10.1016\/j.xkme.2025.101141_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/sonc.2002.34872","article-title":"Metabolism and mechanisms of action of bendamustine: rationales for combination therapies","volume":"29","author":"Gandhi","year":"2002","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.xkme.2025.101141_bib20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-023-00929-0","article-title":"Bendamustine vs. fludarabine\/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma","volume":"13","author":"Sidana","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.xkme.2025.101141_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-009637","article-title":"The use of rituximab and bendamustine in treating chronic lymphocytic leukaemia (CLL) in end-stage renal disease (ESRD)","volume":"2013","author":"Shoji","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"14","key":"10.1016\/j.xkme.2025.101141_bib22","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1200\/JCO.23.02232","article-title":"Development and validation of a prediction model of outcome after B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in relapsed\/refractory multiple myeloma","volume":"42","author":"Gagelmann","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059525001773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:05:48Z","timestamp":1773813948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059525001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2590059525001773"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101141","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T-Cell Therapy in Dialysis-Dependent Patients With Multiple Myeloma: Insights From a 5-Case Series","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2025.101141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101141"}}